N.Y. biotech firm obtains license from Jefferson for cancer-fighting technology

BioVaxys, a biotechnology company with offices in New York and Radnor has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially to treat ovarian cancer, melanoma, and other solid tumor types. Financial terms of the deal are being kept confidential. “Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,”…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news